Evaluation of efficacy of QR 678 and QR678 neo hair growth factor formulation for the treatment of female pattern alopecia in patients with PCOS—A prospective study

Abstract

Background Hair is an essential identity of women. Femininity, sexuality, attractiveness, and personality are symbolically linked to a woman’s hair. Female pattern hair loss is found in 20%‐30% of patients with polycystic ovary syndrome (PCOS). Aim The aim of the present study was to evaluate the efficacy of QR678® and QR678 Neo® therapy in the treatment of female alopecia with PCOS. Method A total of 20 females diagnosed with PCOS in the age 25‐50 years, with complaints of female pattern alopecia with Ludwig, grades I, and II were selected for the study. At each visit, 1.5 ml solution of QR678® was injected in the scalp skin of patients. A total of eight sessions were performed at an interval of 3 week each. All the patients were evaluated with standard global photography at baseline, 4th and 8th session, and 2 months after 8th session. Result Marked improvement was seen in the global photographic assessment score (mean = 8) which was maintained for over 1 year. In videomicroscopic assessment, after four sessions the patients had 8.07 fewer vellus hair, 6.07 more terminal hair, and average hair shaft diameter was 0.82 μm wider. After eight sessions, they had 11.66 fewer vellus hair, 13.77 more terminal hair, and hair shaft diameter was 2.86 μm wider than at baseline. Conclusion Intra‐dermal injections of QR 678® hair growth factor formulation is an effective option for female pattern alopecia with PCOS. This is the first of its kind study using QR678® and QR678 Neo® in PCOS patients.

Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 Neo® hair regrowth formulation for the treatment of Androgenetic Alopecia—A prospective study

“…Considerable decrease in hair fall was noted in 83% of the participants. Treatment was well tolerated by all patients 13‐17 …”

“…A comparitive study of QR678 Neo ® with minoxidil and finasteride found that in advanced Alopecia, QR678 Neo ® may be more effective when given in combination with topical minoxidil and oral finasteride. All these studies have mentioned use of intradermal injection technique to deliver the formulation, and it showed a significant amount of benefit in all the parameters 12‐16 …”

“…The previous studies proved its effectiveness in preventing loss of hair and stimulating new hair growth in comparison to PRP therapy. Also, the therapy has proved to be effective for hair loss treatment in female patients with hair loss caused by PCOS, in alopecia areata cases, and in post‐cancer chemotherapy patients 12‐17 …”

Efficacy of QR678 Neo® hair growth factor formulation for the treatment of hair loss in Covid‐19‐induced persistent Telogen Effluvium—A prospective, clinical, single‐blind study

“…QR678 Neo ® has growth factors such as vascular endothelial growth factor, basic fibroblast growth factor, insulin‐like growth factor‐1, keratinocyte growth factor, and copper tripeptide 1 or their biomimetic peptides which when administered into the scalp decreases the number of vellus hair, increases the terminal hair and hair shaft diameter. It also causes hair regrowth where the hair follicle is present but in dormant stage 12,13 …”

“Comparison of QR 678® & QR678® Neo as monotherapy and as combination therapy with 5% Minoxidil solution and oral Finasteride in the treatment of male androgenetic alopecia—Which is better?”

“…These agents are beneficial in controlling hair loss, but can only induce minimal new hair growth. 2 A new formulation, introduced by Kapoor and Shome in 2018 named QR678 Neo ® (US patent 2017, Indian Patent & Indian FDA approval 2019), is a plant-derived polypeptide solution which comprises of concentration of biomimetic peptides in a titrated manner. 3 QR678 Neo ® already proved its effectiveness in hair regrowth therapy for male and female pattern hair loss, and has also been to be more efficacious than PRP.…”